Status | Study |
Recruiting |
Study Name: Follow-up Study for Patients Who Completed Study ALX0681-C301 (Post-HERCULES) Condition: Acquired Thrombotic Thrombocytopenic Purpura Date: 2016-08-04 Interventions: Biological: caplacizumab |
Terminated |
Study Name: IdeS in Asymptomatic Asymptomatic Antibody-Mediated Thrombotic Thrombocytopenic Purpura (TTP) Patients Condition: Purpura, Thrombotic Thrombocytopenic Date: 2016-07-27 Interventions: Biological: HMed-IdeS One dose of 0.25 mg/kg BW HMed-IdeS on study day 0. Following and evaluation of ef |
Enrolling by invitation |
Study Name: The Role of Microparticles as a Biomarker Condition: Atypical Hemolytic Uremic Syndrome Thrombotic Thrombocytopenic Purpura Date: 2015-10-20 |
Recruiting |
Study Name: Phase III Trial With Caplacizumab in Patients With Acquired Thrombotic Thrombocytopenic Purpura Condition: Acquired Thrombotic Thrombocytopenic Purpura Date: 2015-09-14 Interventions: Biological: caplacizumab Other |
Completed |
Study Name: Phase 1 Dose Escalation, Single Dose Study to Assess Safety and Pharmacokinetics of BAX930 in Hereditary Thrombotic Thrombocytopenic Purpura (TTP) Condition: Hereditary Thrombotic Thrombocytopenic Purpura (TTP) Date: 2014-08-12 Interventions: Drug: Recombinant ADAMTS13 rADAMTS13 (a disintegrin and me |
Active, not recruiting |
Study Name: Early Predictive Factors of Cardiac and Cerebral Involvement in TMA Condition: Thrombotic Microangiopathies Thrombotic Thrombocytopenic Purpura Date: 2014-03-24 Interventions: Other: Biological and imaging investigations From day 1 to day 3, specific blood tests will be performed |
Not yet recruiting |
Study Name: Octaplas Adult TTP Trial Condition: Thrombotic Thrombocytopenic Purpura Date: 2013-09-02 Interventions: Biological: Octaplas Drug: Standard Plasma |
Enrolling by invitation |
Study Name: A Pilot Study of N-acetylcysteine in Thrombotic Thrombocytopenia Purpura Condition: Purpura, Thrombotic Thrombocytopenic TTP Date: 2013-02-22 Interventions: Drug: N-Acetylcysteine IV administration of N-Acetylcysteine at 150mg/kg over 60 min first, then if well |
Withdrawn |
Study Name: Prophylactic Plasma Infusion Therapy for Congenital Thrombotic Thrombocytopenic Purpura Condition: Purpura, Thrombotic Thrombocytopenic Date: 2012-12-12 Interventions: Drug: Octaplas infusion and placebo (group 1) |
Recruiting |
Study Name: Low Dose Rituximab in Thrombotic Thrombocytopenic Purpura Condition: Thrombotic Thrombocytopenic Purpura Date: 2012-03-08 Interventions: Biological: rituximab rituximab intravenously 100 mg every week for four doses |